Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome

Expert Review of Clinical Pharmacology
Rabia ChaudhryAnthony S Wierzbicki

Abstract

A spectrum of disorders, ranging from rare severe cases of homozygous null lipoprotein lipase deficiency (LPLD)-familial chylomicronemia syndrome (FCS) to heterozygous missense LPLD or polygenic causes, result in hypertriglyceridemia and pancreatitis. The effects of mutations are exacerbated by environmental factors such as diet, pregnancy, and insulin resistance. Areas covered: In this review, authors discuss chronic treatment of FCS by ultra-low fat diets allied with the use of fibrates, omega-3 fatty acids, niacin, statins, and insulin-sensitizing therapies depending on the extent of residual lipoprotein lipase (LPL) activity; novel therapies in development target triglyceride (TG)-rich lipoprotein particle clearance. Previously, a gene therapy approach to LPL-alipogene tiparvovec showed that direct targeting of LPL function reduced pancreatitis events. An antisense oligonucleotide to apolipoprotein-C3, volanesorsen has been shown to decrease TGs by 70-80% and possibly to reduce rates of pancreatitis admissions. Studies are underway to validate its long-term efficacy and safety. Other approaches investigating the role of LPL modulating proteins such as angiopoietin-like petide-3 (ANGPTL3) are under consideration. Expert opin...Continue Reading

References

Nov 15, 1979·The New England Journal of Medicine·A P GoldbergE A Nikkila
Oct 1, 1992·Metabolism: Clinical and Experimental·W O RichterP Schwandt
Mar 1, 1982·The Medical Clinics of North America·J D Brunzell, E L Bierman
Jan 10, 1996·JAMA : the Journal of the American Medical Association·R G Bakker-ArkemaD M Black
Nov 30, 1996·Lancet·A S Wierzbicki, T M Reynolds
Jul 1, 1997·Arteriosclerosis, Thrombosis, and Vascular Biology·M RouisS Santamarina-Fojo
Apr 4, 1998·The American Journal of Cardiology·E A SteinP Laskarzewski
Apr 13, 1999·The Journal of Clinical Endocrinology and Metabolism·A P HeaneyP N Durrington
Jul 31, 1999·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·A LennertzT Bosch
Jan 17, 2002·The American Journal of Cardiology·Anthony S WierzbickiMartin A Crook
Feb 6, 2002·Bioscience, Biotechnology, and Biochemistry·G R ZhaoX M Du
Jul 20, 2004·Journal of Lipid Research·Shobha H GanjiMoti L Kashyap
Oct 4, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Daniel J Rader
Feb 10, 2006·Current Medical Research and Opinion·A VogtUNKNOWN NAUTILUS Study Group
Apr 20, 2006·International Journal of Clinical Practice·A S Wierzbicki
Aug 19, 2007·Molecular BioSystems·Daniel A BlasioleAlan D Attie
Sep 7, 2007·The New England Journal of Medicine·John D Brunzell
Jan 18, 2008·Veterinary Surgery : VS·James T GilesKenneth E Bartels
Jun 14, 2008·The American Journal of Cardiology·Vaijinath S Kamanna, Moti L Kashyap
Apr 11, 2008·Gene Therapy·I E AlexanderJ Christodoulou
Nov 11, 2008·Current Diabetes Reviews·Ioanna EleftheriadouNicholas Tentolouris
Feb 10, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Chuchun L ChangRichard J Deckelbaum
Apr 10, 2009·Current Drug Targets·Adie Viljoen, Anthony S Wierzbicki
Aug 8, 2009·Clinical Genetics·R A Stein
Sep 3, 2009·Annals of the New York Academy of Sciences·Kyung Suk ParkHyeyoung Kim
Nov 17, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Carlos O MendivilFrank M Sacks
Mar 17, 2010·Pharmacology & Therapeutics·Philippe Costet
Jul 27, 2010·Nature Genetics·Christopher T JohansenRobert A Hegele
Jul 29, 2010·Current Medical Research and Opinion·Anthony S WierzbickiRichard Wray
Nov 19, 2011·Arteriosclerosis, Thrombosis, and Vascular Biology·Esther M M OoiDennis L Sprecher
Mar 23, 2012·The Journal of Clinical Endocrinology and Metabolism·André C CarpentierDaniel Gaudet

❮ Previous
Next ❯

Citations

Oct 18, 2018·Expert Review of Clinical Pharmacology·Bogusław OkopieńAleksandra Bołdys
Apr 30, 2019·Annals of Internal Medicine·Alan Chait, Robert H Eckel
Nov 14, 2019·European Journal of Preventive Cardiology·Vincent A PallazolaSeth S Martin
Jun 7, 2019·Current Opinion in Cardiology·Anthony S Wierzbicki, Timothy M Reynolds
Mar 17, 2019·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Emmanuel Eroume-A EgomVincent M G Maher
Aug 23, 2019·Current Opinion in Cardiology·Ricky LaliGuillaume Paré
Oct 3, 2020·Pediatrics in Review·Carsten KruegerAndreas Schulze
Aug 28, 2020·Current Atherosclerosis Reports·Antonio GalloEric Bruckert
Feb 19, 2021·Revista brasileira de ginecologia e obstetrícia : revista da Federação Brasileira das Sociedades de Ginecologia e Obstetrícia·Julia Cristina Coronado ArroyoFrancisca Elena Zavaleta Gutiérrez
May 20, 2021·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Beatriz Candás-EstébanezVirginia Esteve-Luque
May 27, 2021·Pediatric Annals·Scott Leopold, Justin P Zachariah

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Related Papers

Expert Review of Cardiovascular Therapy
Adie Viljoen, Anthony S Wierzbicki
Expert Opinion on Biological Therapy
Anthony S Wierzbicki, Adie Viljoen
Current Opinion in Lipidology
Steven E Gryn, Robert A Hegele
© 2022 Meta ULC. All rights reserved